Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antiretroviral therapy

- PMLiVE

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

The FDA also issued an EUA for the treatment to include non-hospitalised paediatric patients 12 years and under who are at high risk of disease progression

- PMLiVE

Vir Biotech launches new research programme for HIV and malaria prevention

Using antibody research, Vir will combine its existing immunology and virology expertise with the Gates Foundation

- PMLiVE

Gilead’s Trodelvy approved for triple-negative breast cancer in Europe

European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy

- PMLiVE

Gilead to pay $745m for three oncology programmes from Arcus Biosciences

The deal will enable Gilead to accelerate the development of candidate molecules and explore treatment combinations with long-term partner Arcus Biosciences

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

- PMLiVE

Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury

The company has had a ‘very strong’ third quarter in spite of a sharp decline in its HIV portfolio due to generic competition

- PMLiVE

Gilead’s Trodelvy set for EU approval in breast cancer

The positive opinion from EMA’s CHMP means Trodelvy could be available as second-line treatment for unresectable or metastatic breast cancer before the end of the year

- PMLiVE

Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%

New data showing Gilead’s Veklury cuts the risk of hospitalisation for COVID-19 contradicts results of the World Health Organization’s Solidarity study

- PMLiVE

Gilead reveals real-world data for COVID-19 drug Veklury

Veklury significantly lowered the risk of mortality compared with matched controls in real-world analysis, says Gilead

- PMLiVE

Kite partners with Shoreline Biosciences to develop allogeneic cell therapies

The deal could be worth a total of up to $2.3bn, with Shoreline receiving an undisclosed upfront payment

- PMLiVE

Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit

Total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020

- PMLiVE

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

FDA approved the antibody-drug conjugate in this indication in April 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links